Gabather (GABA) Investor Update summary

Company background and focus

• Over 10 years of experience in drug development for mental health disorders, originating from university research and now listed on Nasdaq and First North Growth Market.

• Focused on neuropsychiatric disorders with significant unmet medical needs and societal impact, developing next-generation drugs targeting selective GABAA stimulators.

• Lead candidate GT-002 is in clinical development for cognitive impairment in mental disorders, with potential applications in schizophrenia, psychosis, Alzheimer's, autism, dementia, healthy aging, and long-term COVID.

• Gabather is listed on First North Growth Market; Corpura Fondkommission AB acts as Certified Adviser.

Clinical development and trial status

• GT-002 has completed three Phase I studies with no observed side effects, demonstrating safety and brain penetration.

• Phase II clinical trial in schizophrenia patients is fully funded, with all logistics and approvals in place, starting in Q1.

• The trial uses a crossover design, comparing placebo, GT-002, and a reference compound within the same patients for high-quality data.

• Preliminary data from the trial expected in Q3, with ongoing publication and information flow.

Innovation and market potential

• GT-002 offers a novel approach to cognitive impairment in schizophrenia, distinct from traditional dopamine and glutamate targeting drugs.

• The drug is orally available, well-tolerated, suitable for once-daily dosing, and has scalable production.